Eric Jonasch, MD, is Associate Professor in the Department of Genitourinary Medicine at The University of Texas MD Anderson Cancer Center. He completed his medical education at McGill University in Montreal, Canada, and his fellowship at the Beth Israel Deaconess Medical Center. Dr. Jonasch is board certified in medical oncology, hematology, and internal medicine by the American Board of Internal Medicine, and in oncology and medicine by the Royal College of Physicians & Surgeons of Canada. His professional memberships include the American Association for Cancer Research and ASCO. He is a member of the NCCN Guidelines Panel for Kidney and Testicular Cancers. Dr. Jonasch is also a medical advisor for the Kidney Cancer Association and the von Hippel-Lindau Family Alliance.
Dr. Jonasch has authored more than 80 peer-reviewed articles, several book chapters, and a textbook on kidney cancer, and has presented at numerous national and international conferences.
Dr. Jonasch’s research interests include renal cell carcinoma, von Hippel-Lindau disease, and defining the determinants of response and resistance to antiangiogenic agents. He is principal investigator of a National Institutes of Health Roadmap initiative grant, and several industry and institutionally sponsored research grants.
Robert J. Motzer, MD, is a medical oncologist at Memorial Sloan-Kettering Cancer Center, with a primary area of expertise in kidney (renal cell carcinoma) and testicular cancer (germ-cell tumor), and has led more than 50 clinical trials for these cancers both nationally and internationally. Through this research, he helped identify 3 targeted antiangiogenesis drugs that serve as effective first- or second-line treatments for patients with advanced kidney cancer. Dr. Motzer helped develop a system to aid in predicting outcomes for patients taking medications for advanced kidney cancer—a tool now widely applied by physicians around the world to direct the care of patients.
In addition to publishing more than 300 original articles, scientific reviews, chapters, and abstracts, Dr. Motzer has lectured on kidney and testicular cancer care internationally and worked to improve cancer care through health care policy and advocacy activities. Dr. Motzer chairs the NCCN Guidelines Panels for Kidney and Testicular Cancers.
Dr. Motzer graduated from the University of Michigan Medical School and has received the Career Development Award from the NIH and the Willet F. Whitmore Award for Clinical Excellence from Memorial Sloan-Kettering.
The ideas and viewpoints expressed in this editorial are those of the author and do not necessarily represent any policy, position, or program of NCCN.